CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
about
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastomaTargeting Cell Survival Proteins for Cancer Cell DeathSelective targeting of the stress chaperome as a therapeutic strategyHeat shock protein 90 inhibition: rationale and clinical potential.Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphomaProteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.Impact of metal binding on the antitumor activity and cellular imaging of a metal chelator cationic imidazopyridine derivative.Probing the probes: fitness factors for small molecule tools.Protein chaperones: a composition of matter review (2008 - 2013).Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsAUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cellsHsp90 molecular chaperone inhibitors: are we there yet?Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94The preclinical discovery of amyotrophic lateral sclerosis drugs.CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease.Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.Molecular basis for the actions of Hsp90 inhibitors and cancer therapy.A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerAdvances in HSP27 and HSP90-targeting strategies for glioblastoma.Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape-Based Similarity Screening.Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum
P2860
Q24607424-41D5ABCB-D22B-46E2-9B63-2F1670F1D4CAQ26765447-B30B52BE-294D-4A91-8CEE-14AF84081590Q28248791-EF74D708-AADB-44DE-BC95-6E87891CBBA8Q30418761-C30FB4B5-A4E4-485F-B5FE-A4D58BCC047DQ30498194-B0DE11B0-6796-4B7A-9F99-8146FA5CB0C4Q33668999-C6E22B09-E515-4CDC-8852-4B17E61813A4Q33710107-8E0F4CF0-2772-4814-B26D-3CB200F7B827Q33853785-EF195094-AC6B-476D-A468-AE4209BE4E6CQ34001269-705EE074-00C6-47A8-9999-1B97867E688FQ34013266-1D877A8D-B072-4295-B58C-2EFF08744BBAQ34164027-1CA74BD4-EED0-4075-B937-BD6562B882EAQ35188254-3330EBE0-B0A3-4B2C-96E2-55CB32098190Q35655105-7D585089-F830-4307-9CA0-D29ADB57B247Q35800838-017A18CD-8D10-4178-9538-6C131168752AQ35899122-D05FA805-09D4-487B-A733-2753BACD1C22Q36009915-733CA7ED-3BD0-44D6-ABD2-4AC77589CAE2Q36442900-5FACB2BD-6AED-43E9-BB61-21739F746081Q36688951-6599CDC0-255A-476B-BC2D-59DBAD9068D0Q36890658-F3599C7E-0BC0-48BD-95CD-B0524F63F6C2Q37198085-BB18A649-B658-40C2-BF11-AF4A31409792Q37891987-593AD1C5-F84B-49FE-80BE-ACE77F1EFD03Q37910724-B0675C47-B754-41F5-8FF3-C0A2E9794EEFQ38648408-2DCA4CF2-E8D4-4C8F-9166-83920B93C0C6Q38722149-62DAFEF6-7270-45A3-B1FB-509CE5010B2EQ38735183-0590D85B-3BD6-49C9-86BA-4E230B944861Q39002157-2C02E5CA-1583-490E-B2C6-1305A3090149Q39425771-8AEF0469-5128-4764-B52C-AAA1956E9B08Q50942188-798CA058-3902-414E-9C89-F560E9BBEB4DQ51598140-AAE69A9F-68F2-4A97-9FF0-B5D50CE8F09CQ53621063-2C00E390-283A-4918-8138-F122948DCF53Q56355675-575D99DB-92AD-4BFF-821D-8849BA7F567F
P2860
CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
CUDC-305, a novel synthetic HS ...... properties for cancer therapy.
@en
CUDC-305, a novel synthetic HS ...... properties for cancer therapy.
@nl
type
label
CUDC-305, a novel synthetic HS ...... properties for cancer therapy.
@en
CUDC-305, a novel synthetic HS ...... properties for cancer therapy.
@nl
prefLabel
CUDC-305, a novel synthetic HS ...... properties for cancer therapy.
@en
CUDC-305, a novel synthetic HS ...... properties for cancer therapy.
@nl
P2093
P1476
CUDC-305, a novel synthetic HS ...... properties for cancer therapy.
@en
P2093
Brian Zifcak
Changgeng Qian
Cheng-Jung Lai
Dagong Wang
Guang-Xin Xu
Hai-Xiao Zhai
Jeffrey Forrester
P304
P356
10.1158/1078-0432.CCR-09-0152
P407
P577
2009-06-09T00:00:00Z